查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951867

罕见疾病个人化治疗方案市场分析及预测（至2035年）：按类型、产品、服务、技术、组件、应用、最终用户、部署方式、解决方案和阶段划分

Personalized Treatment Plans for Rare Diseases Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Deployment, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 344 Pages | 商品交期: 3-5个工作天内

价格
简介目录

罕见疾病个人化治疗方案市场预计将从2024年的1,847亿美元成长到2034年的5,167亿美元，复合年增长率约为12.8%。该市场涵盖针对罕见疾病患者独特的基因和分子特征而设计的个人化治疗策略。它整合了基因组学、先进的诊断技术和精准医疗，以提高治疗效果并改善患者预后。人们对该领域的认识不断提高以及生物技术领域的进步正在推动市场成长，为新药研发和个人化医疗解决方案创造了机会。

受基因组学和生物技术进步的推动，罕见疾病个人化治疗方案市场正经历强劲成长。治疗领域成长最为迅猛，基因疗法和生物製药凭藉其精准性和有效性占据主导地位。基于基因谱定製药物治疗的药物基因组学紧随其后，体现了其改善治疗效果的巨大潜力。在诊断领域，次世代定序（NGS）和生物标记发现技术在识别罕见基因突变方面日益重要。伴随诊断也在蓬勃发展，为个人化治疗策略提供支持。包括人工智慧驱动平台和远端医疗的数位健康技术正成为促进患者管理和监测的重要基础。製药公司、研究机构和技术提供者之间的创新合作正在推动市场成长。以患者为中心的理念和监管奖励进一步推动了个人化治疗的发展，并有望改善罕见疾病患者的生活品质。

市场区隔
类型 基因检测、生物标记鑑定、药物基因体学、代谢体学、蛋白质体学
产品 诊断试剂盒、治疗药物、穿戴式装置、伴随诊断
服务 咨询服务、基因测序服务、数据分析服务、病患监测
科技 CRISPR技术、次世代定序、人工智慧、机器学习
成分 软体、硬体和平台
应用领域 肿瘤学、心臟病学、神经病学、免疫学、内分泌学
最终用户 医院、研究机构、生物製药公司、诊断检查室
实施表格 云端部署、本地部署、混合部署
解决方案 临床决策支援、病患管理和数据集成
步 早期研究、临床开发、商业化和上市后监测

罕见疾病个人化治疗方案市场的特征是市场份额分布动态变化，这主要受创新定价策略和前沿产品发布的影响。各公司致力于开发满足罕见疾病患者独特需求的个人化解决方案。这种对客製化的关注加剧了市场竞争，并鼓励新参与企业推出先进的治疗方案。市场正经历着策略联盟和伙伴关係关係的激增，旨在加强产品供应并拓展市场。竞争标竿分析显示，主要参与者不断优化其策略以保持竞争优势。监管影响至关重要，严格的指导方针塑造产品开发和核准流程。区域监管差异也会影响市场，并可能促进或阻碍成长。先进的分析技术、以患者为中心的理念和技术创新对于推动市场发展至关重要。增强的资料收集和分析能力对于进行全面的市场分析至关重要，能够提供对新兴趋势和机会的洞察。

主要趋势和驱动因素：

受多种关键趋势和驱动因素的影响，罕见疾病个人化治疗方案市场正在经历变革时期。其中最重要的趋势之一是基因组技术的进步，该技术能够精准识别导致罕见疾病的基因突变，从而製定针对患者特定基因谱的个人化治疗方案。这不仅改善了治疗效果，也减少了副作用。另一个趋势是製药公司、研究机构和医疗服务提供者之间合作的日益增加。这些合作正在促进创新，加速个人化治疗方法的研发。真实世界数据的日益丰富和先进分析技术的进步也增强了个人化治疗策略的设计能力，进一步推动了市场成长。驱动因素包括罕见病患疾病率的上升和患者未被满足的需求。各国政府和监管机构正加强支持个人化医疗的发展，包括资助相关研究和简化罕见疾病药物的核准流程。此外，患者权益倡导组织在提高公众意识和拓展个人化治疗方案方面发挥关键作用。在医疗基础设施完善且对罕见疾病认知不断提高的发展中市场，新的机会正在出现。能够提供经济高效且便捷的个人化治疗方案的公司，在开拓这些市场方面占据了有利地位。数位健康科技和远端医疗的融合，也扩大了个人化治疗方案的覆盖范围和有效性，从而带来了更大的成长潜力。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 基因检测
    • 生物标记鑑定
    • 药物基因组学
    • 代谢体学
    • 蛋白质体学
  • 市场规模及预测：依产品划分
    • 诊断试剂盒
    • 治疗药物
    • 穿戴式装置
    • 伴随诊断
  • 市场规模及预测：依服务划分
    • 咨询服务
    • 基因测序服务
    • 数据分析服务
    • 病患监测
  • 市场规模及预测：依技术划分
    • CRISPR技术
    • 次世代定序
    • 人工智慧
    • 机器学习
  • 市场规模及预测：依组件划分
    • 软体
    • 硬体
    • 按平台
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 免疫学
    • 内分泌学
  • 市场规模及预测：依最终用户划分
    • 医院
    • 研究所
    • 生物製药公司
    • 诊断检查室
  • 市场规模及预测：依发展状况
    • 基于云端的
    • 本地部署
    • 杂交种
  • 市场规模及预测：按解决方案划分
    • 临床决策支持
    • 病患管理
    • 数据集成
  • 市场规模及预测：依阶段划分
    • 早期调查
    • 临床开发
    • 商业化
    • 上市后监测

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 其他亚太地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Genmab
  • Sarepta Therapeutics
  • Ultragenyx Pharmaceutical
  • Bio Marin Pharmaceutical
  • PTC Therapeutics
  • Spark Therapeutics
  • Bluebird Bio
  • Ionis Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amicus Therapeutics
  • Vertex Pharmaceuticals
  • REGENXBIO
  • uni Qure
  • Sangamo Therapeutics
  • Audentes Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Beam Therapeutics
  • Rocket Pharmaceuticals

第九章：关于我们

简介目录
Product Code: GIS32832

Personalized Treatment Plans for Rare Diseases Market is anticipated to expand from $184.7 billion in 2024 to $516.7 billion by 2034, growing at a CAGR of approximately 12.8%. The Personalized Treatment Plans for Rare Diseases Market encompasses tailored therapeutic strategies designed to address the unique genetic and molecular profiles of patients with uncommon disorders. This market integrates genomics, advanced diagnostics, and precision medicine to enhance treatment efficacy and patient outcomes. Increasing awareness and advancements in biotechnology are propelling growth, with opportunities in novel drug development and personalized healthcare solutions.

The Personalized Treatment Plans for Rare Diseases Market is experiencing robust growth, driven by advancements in genomics and biotechnology. The therapeutic segment is the top performer, with gene therapies and biologics leading due to their precision and effectiveness. Pharmacogenomics, which tailors drug therapy based on genetic profiles, is a close second, reflecting its potential to enhance treatment outcomes. The diagnostic segment follows, with next-generation sequencing (NGS) and biomarker discovery gaining prominence for their role in identifying rare genetic mutations. Companion diagnostics are also rising, supporting personalized treatment strategies. Digital health technologies, including AI-driven platforms and telemedicine, are emerging as vital enablers, facilitating patient management and monitoring. Innovative collaborations between pharmaceutical companies, research institutions, and technology providers are accelerating market growth. The emphasis on patient-centric approaches and regulatory incentives further propels the development of tailored therapies, promising improved quality of life for individuals with rare diseases.

Market Segmentation
TypeGenetic Testing, Biomarker Identification, Pharmacogenomics, Metabolomics, Proteomics
ProductDiagnostic Kits, Therapeutic Agents, Wearable Devices, Companion Diagnostics
ServicesConsultation Services, Genomic Sequencing Services, Data Analysis Services, Patient Monitoring
TechnologyCRISPR Technology, Next-Generation Sequencing, Artificial Intelligence, Machine Learning
ComponentSoftware, Hardware, Platform
ApplicationOncology, Cardiology, Neurology, Immunology, Endocrinology
End UserHospitals, Research Institutes, Biopharmaceutical Companies, Diagnostic Laboratories
DeploymentCloud-Based, On-Premise, Hybrid
SolutionsClinical Decision Support, Patient Management, Data Integration
StageEarly-Stage Research, Clinical Development, Commercialization, Post-Market Surveillance

The Personalized Treatment Plans for Rare Diseases Market is characterized by dynamic market share distribution, influenced by innovative pricing strategies and the launch of cutting-edge products. Companies are increasingly focusing on developing personalized solutions that cater to the unique needs of patients with rare diseases. This focus on customization is driving competition and encouraging new entrants to introduce advanced treatment options. The market is witnessing a surge in strategic collaborations and partnerships aimed at enhancing product offerings and expanding market reach. Competition benchmarking reveals a landscape where key players are continually optimizing their strategies to maintain a competitive edge. Regulatory influences play a critical role, with stringent guidelines shaping product development and approval processes. The market is also impacted by regional regulatory variations, which can either facilitate or hinder market growth. Advanced analytics, patient-centric approaches, and technological innovations are pivotal in driving the market forward. Enhanced data collection and analysis capabilities are essential for comprehensive market analysis, offering insights into emerging trends and opportunities.

Geographical Overview:

The personalized treatment plans for rare diseases market is witnessing substantial growth across diverse regions. North America leads the market, driven by advanced healthcare infrastructure and robust research initiatives. The region's commitment to precision medicine and strong government support enhances its market position. Europe follows, with its focus on rare disease research and patient-centric healthcare systems fostering market expansion. The Asia Pacific region is experiencing rapid growth, propelled by increasing healthcare investments and a rising prevalence of rare diseases. Countries like China and India are emerging as significant players, with advancements in biotechnology and personalized medicine. Latin America is also showing promise, with Brazil and Mexico investing in healthcare innovations. Meanwhile, the Middle East & Africa are recognizing the potential of personalized treatment plans, with countries like the UAE and South Africa focusing on improving healthcare access and quality. These regions present lucrative opportunities for market expansion and development.

Global tariffs and geopolitical tensions are influencing the Personalized Treatment Plans for Rare Diseases Market, particularly in East Asia. Japan and South Korea are enhancing their domestic pharmaceutical capabilities to mitigate risks from trade disputes, while China is investing in biopharmaceutical innovation to reduce dependency on Western imports. Taiwan, though a key player in semiconductor manufacturing, is diversifying its focus towards biotechnology amidst US-China tensions. The global market for personalized treatments is experiencing robust growth, driven by advancements in genomics and AI, but faces challenges from supply chain disruptions and fluctuating energy prices, partly due to Middle East conflicts. By 2035, the market is expected to thrive on strategic partnerships and increased resilience in supply chains, with East Asian countries playing pivotal roles in global biopharma innovation.

Key Trends and Drivers:

The Personalized Treatment Plans for Rare Diseases Market is experiencing a transformative phase, driven by several key trends and drivers. One of the most significant trends is the advancement in genomic technologies, which enables precise identification of genetic mutations responsible for rare diseases. This allows for tailored treatment plans that target the specific genetic profiles of patients, improving outcomes and reducing adverse effects. Another trend is the growing collaboration between pharmaceutical companies, research institutions, and healthcare providers. These partnerships are fostering innovation and accelerating the development of personalized therapies. The increasing availability of real-world data and advanced analytics is also enhancing the ability to design individualized treatment strategies, further propelling market growth. Drivers include the rising prevalence of rare diseases and the unmet medical needs of patients. Governments and regulatory bodies are increasingly supporting initiatives that promote personalized medicine. This includes funding research and streamlining approval processes for orphan drugs. Additionally, patient advocacy groups are playing a crucial role in raising awareness and pushing for more personalized treatment options. Opportunities are emerging in developing markets where healthcare infrastructure is improving, and awareness of rare diseases is growing. Companies that can offer cost-effective and accessible personalized treatment solutions are well-positioned to capture these markets. The integration of digital health technologies and telemedicine is also expanding the reach and effectiveness of personalized treatment plans, offering further growth potential.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Genetic Testing
    • 4.1.2 Biomarker Identification
    • 4.1.3 Pharmacogenomics
    • 4.1.4 Metabolomics
    • 4.1.5 Proteomics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Diagnostic Kits
    • 4.2.2 Therapeutic Agents
    • 4.2.3 Wearable Devices
    • 4.2.4 Companion Diagnostics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation Services
    • 4.3.2 Genomic Sequencing Services
    • 4.3.3 Data Analysis Services
    • 4.3.4 Patient Monitoring
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR Technology
    • 4.4.2 Next-Generation Sequencing
    • 4.4.3 Artificial Intelligence
    • 4.4.4 Machine Learning
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Software
    • 4.5.2 Hardware
    • 4.5.3 Platform
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Cardiology
    • 4.6.3 Neurology
    • 4.6.4 Immunology
    • 4.6.5 Endocrinology
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Research Institutes
    • 4.7.3 Biopharmaceutical Companies
    • 4.7.4 Diagnostic Laboratories
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Cloud-Based
    • 4.8.2 On-Premise
    • 4.8.3 Hybrid
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Clinical Decision Support
    • 4.9.2 Patient Management
    • 4.9.3 Data Integration
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Early-Stage Research
    • 4.10.2 Clinical Development
    • 4.10.3 Commercialization
    • 4.10.4 Post-Market Surveillance

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Genmab
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sarepta Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Ultragenyx Pharmaceutical
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bio Marin Pharmaceutical
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 PTC Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Spark Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bluebird Bio
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Ionis Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Alnylam Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Amicus Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Vertex Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 REGENXBIO
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 uni Qure
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sangamo Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Audentes Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 CRISPR Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Editas Medicine
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Intellia Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Beam Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Rocket Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us